Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species
Open Access
- 1 March 2014
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 52 (3), 994-997
- https://doi.org/10.1128/jcm.03044-13
Abstract
We reviewed our antifungal susceptibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Candida species and compared resistance rates determined by the previous and recently revised CLSI antifungal breakpoints. With the new breakpoints, resistance was significantly increased for micafungin (from 0.8% to 7.6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (from 6.1% to 18.4%) against Candida glabrata. Resistance was also increased for fluconazole against Candida albicans (from 2.1% to 5.7%).Keywords
This publication has 17 references indexed in Scilit:
- In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and MoldsJournal of Clinical Microbiology, 2013
- Breakthrough Invasive Candidiasis in Patients on MicafunginJournal of Clinical Microbiology, 2010
- Evaluation by Data Mining Techniques of Fluconazole Breakpoints Established by the Clinical and Laboratory Standards Institute (CLSI) and Comparison with Those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)Antimicrobial Agents and Chemotherapy, 2010
- Association of Fluconazole Pharmacodynamics with Mortality in Patients with CandidemiaAntimicrobial Agents and Chemotherapy, 2008
- Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance ProgramJournal of Clinical Microbiology, 2008
- Correlation of the MIC and Dose/MIC Ratio of Fluconazole to the Therapeutic Response of Patients with Mucosal Candidiasis and CandidemiaAntimicrobial Agents and Chemotherapy, 2007
- Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution MethodsJournal of Clinical Microbiology, 2007
- Clinical Significance of Azole Antifungal Drug Cross-Resistance in Candida glabrataJournal of Clinical Microbiology, 2006
- Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility TestingClinical Microbiology Reviews, 2006
- Cross-Resistance between Fluconazole and Ravuconazole and the Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Ravuconazole among 12,796 Clinical Isolates of Candida sppJournal of Clinical Microbiology, 2004